Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia

Sarcoidosis is a systemic disorder of unknown aetiology characterised by the formation of non-caseating epithelioid granulomas in involved organs. Although a spontaneous remission is frequent, up to 28–53% of patients may follow a persistent active course for more than 5 years [1, 2]. Outcome may be severe in a subset of these patients. Sarcoidosis treatment relies on three lines of therapies respectively corticosteroids, immunosuppressive medications and anti-tumour necrosis factor-α (anti-TNF-α) therapy according to severity. Potential role of the JAK-STAT pathway in sarcoidosis <http://ow.ly/L8Du30m78XI> The authors would like to thank J.F. Bernaudin (Dept of Respiratory Diseases, APHP, Avicenne Hospital, Bobigny, France) for his critical review and corrections of the manuscript.